Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Follow-Up Questions
Who is the CEO of Prelude Therapeutics Inc?
Dr. Krishna Vaddi is the Chief Executive Officer of Prelude Therapeutics Inc, joining the firm since 2016.
What is the price performance of PRLD stock?
The current price of PRLD is $1, it has decreased 0.86% in the last trading day.
What are the primary business themes or industries for Prelude Therapeutics Inc?
Prelude Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Prelude Therapeutics Inc market cap?
Prelude Therapeutics Inc's current market cap is $56.6M
Is Prelude Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Prelude Therapeutics Inc, including 3 strong buy, 5 buy, 1 hold, 1 sell, and 3 strong sell
